Benzinga | Aug 7, 2020 07:22AM EDT

Aclaris Therapeutics Q2 EPS $(0.28); Sales $2.04M

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.28) per share. This is a 63.16 percent increase over losses of $(0.76) per share from the same period last year.Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.28) per share. This is a 63.16 percent increase over losses of $(0.76) per share from the same period last year.